Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772147/
https://ncbi.nlm.nih.gov/pubmed/31124580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15969
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados